Your browser doesn't support javascript.
loading
Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders: an individual participant data meta-analysis on 3053 individuals.
Argote, Mathilde; Sescousse, Guillaume; Brunelin, Jérôme; Baudin, Grégoire; Schaub, Michael Patrick; Rabin, Rachel; Schnell, Thomas; Ringen, Petter Andreas; Andreassen, Ole Andreas; Addington, Jean Margaret; Brambilla, Paolo; Delvecchio, Giuseppe; Bechdolf, Andreas; Wobrock, Thomas; Schneider-Axmann, Thomas; Herzig, Daniela; Mohr, Christine; Vila-Badia, Regina; Rodie, Judith Usall; Mallet, Jasmina; Ricci, Valerio; Martinotti, Giovanni; Knízková, Karolína; Rodriguez, Mabel; Cookey, Jacob; Tibbo, Philip; Scheffler, Freda; Asmal, Laila; Garcia-Rizo, Clemente; Amoretti, Silvia; Huber, Christian; Thibeau, Heather; Kline, Emily; Fakra, Eric; Jardri, Renaud; Nourredine, Mikail; Rolland, Benjamin.
Afiliação
  • Argote M; PSYR, CNRL, INSERM U1028, CNRS UMR5292, UCBL1, Bron, France.
  • Sescousse G; Université Claude Bernard Lyon 1, Lyon, France.
  • Brunelin J; Centre Hospitalier Le Vinatier, Bron, France.
  • Baudin G; PSYR, CNRL, INSERM U1028, CNRS UMR5292, UCBL1, Bron, France.
  • Schaub MP; Université Claude Bernard Lyon 1, Lyon, France.
  • Rabin R; Centre Hospitalier Le Vinatier, Bron, France.
  • Schnell T; PSYR, CNRL, INSERM U1028, CNRS UMR5292, UCBL1, Bron, France.
  • Ringen PA; Université Claude Bernard Lyon 1, Lyon, France.
  • Andreassen OA; Centre Hospitalier Le Vinatier, Bron, France.
  • Addington JM; Laboratoire de Psychopathologie et Processus de Santé, Université Paris Cité, F-92100, France.
  • Brambilla P; Swiss Research Institute for Public Health and Addiction ISGF, University of Zurich, Zurich, Switzerland.
  • Delvecchio G; Department of Psychiatry, McGill University, Montreal, Canada.
  • Bechdolf A; Medical School Hamburg, University of Applied Sciences and Medical University, Hamburg, Germany.
  • Wobrock T; NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway.
  • Schneider-Axmann T; NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital and University of Oslo, Oslo, Norway.
  • Herzig D; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Mohr C; Department of Psychiatry, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.
  • Vila-Badia R; Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Rodie JU; Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • Mallet J; Department of Neurosciences and Mental Health, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Ricci V; Department of Psychiatry, Psychotherapy und Psychosomatic, Vivantes Klinikum am Urban und Vivantes Klinikum im Friedrichshain, Berlin, Germany.
  • Martinotti G; Department of Psychiatry and Psychotherapy, CCM, Charite-Universitätsmedizin Berlin, Berlin, Germany.
  • Knízková K; Centre for Mental Health, County Hospitals Darmstadt-Dieburg, Groß-Umstadt, Germany.
  • Rodriguez M; Department of Psychiatry and Psychotherapy, Georg-August University Göttingen, Germany.
  • Cookey J; Department of Psychiatry and Psychotherapy, Ludwig Maximillian University Munich, Munich, Germany.
  • Tibbo P; Clienia Littenheid AG, Psychiatrische Tagesklinik Frauenfeld, 8500, Frauenfeld, Switzerland.
  • Scheffler F; Department of Experimental Psychology, University of Bristol, Bristol, UK.
  • Asmal L; Université de Lausanne, Institute of Psychology (IP), Lausanne, Switzerland.
  • Garcia-Rizo C; Department of Experimental Psychology, University of Bristol, Bristol, UK.
  • Amoretti S; Université de Lausanne, Institute of Psychology (IP), Lausanne, Switzerland.
  • Huber C; Etiopathogenesis and Treatment of Severe Mental Disorders (MERITT), Institut de Recerca Sant Joan de Déu, Spain.
  • Thibeau H; Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain.
  • Kline E; Etiopathogenesis and Treatment of Severe Mental Disorders (MERITT), Institut de Recerca Sant Joan de Déu, Spain.
  • Fakra E; Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain.
  • Jardri R; Université Paris Cité, INSERM UMR1266, Institute of Psychiatry and Neuroscience of Paris France, France.
  • Nourredine M; AP-HP, Department of Psychiatry, Louis Mourier Hospital, Colombes, France.
  • Rolland B; Department of Neuroscience, San Luigi Gonzaga University Hospital, 10043, Orbassano, Italy.
EClinicalMedicine ; 64: 102199, 2023 Oct.
Article em En | MEDLINE | ID: mdl-37731936
ABSTRACT

Background:

The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not been investigated. In addition, meta-analyses use aggregated data discarding important confounding variables which is a source of bias.

Methods:

PubMed, ScienceDirect and PsycINFO were used to search for publications from inception to September 27, 2022. We contacted the authors of relevant studies to extract raw datasets and perform an Individual Participant Data meta-analysis (IPDMA). Inclusion criteria were psychopathology of individuals with schizophrenia spectrum disorders assessed by the Positive and Negative Syndrome Scale (PANSS); cannabis-users had to either have a diagnosis of cannabis use disorder or use cannabis at least twice a week. The main outcomes were the PANSS subscores extracted via the 3-factor (positive, negative and general) and 5-factor (positive, negative, disorganization, depression, excitement) structures. Preregistration is accessible via Prospero ID CRD42022329172.

Findings:

Among the 1149 identified studies, 65 were eligible and 21 datasets were shared, totaling 3677 IPD and 3053 complete cases. The adjusted multivariate analysis revealed that relative to non-use, cannabis use was associated with higher severity of positive dimension (3-factor Adjusted Mean Difference, aMD = 0.34, 95% Confidence Interval, CI = [0.03; 0.66]; 5-factor aMD = 0.38, 95% CI = [0.08; 0.63]), lower severity of negative dimension (3-factor aMD = -0.49, 95% CI [-0.90; -0.09]; 5-factor aMD = -0.50, 95% CI = [-0.91; -0.08]), higher severity of excitement dimension (aMD = 0.16, 95% CI = [0.03; 0.28]). No association was found between cannabis use and disorganization (aMD = -0.13, 95% CI = [-0.42; 0.17]) or depression (aMD = -0.14, 95% CI = [-0.34; 0.06]).

Interpretation:

No causal relationship can be inferred from the current results. The findings could be in favor of both a detrimental and beneficial effect of cannabis on positive and negative symptoms, respectively. Longitudinal designs are needed to understand the role of cannabis is this association. The reported effect sizes are small and CIs are wide, the interpretation of findings should be taken with caution.

Funding:

This research did not receive any specific grant or funding. Primary financial support for authors was provided by Le Vinatier Psychiatric Hospital.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Idioma: En Ano de publicação: 2023 Tipo de documento: Article